Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study.
The ability of tonabersat to relieve the symptoms of migraine attacks with or without aura was evaluated in a randomized, double-blind, placebo-controlled, multicentre, parallel-group study. Patients received 20 or 40 mg of tonabersat, or 50 mg of sumatriptan (positive control), or placebo at the onset of a moderate or severe attack. Headache intensity, relief and recurrence were recorded for 24 h after dosing. On the basis of primary or secondary efficacy measures, tonabersat did not provide a clinically or statistically significant advantage over placebo. Tonabersat generally was well tolerated and had no effect on vital signs, electrocardiogram recordings or laboratory values. The lack of efficacy may be a function of the slow absorption of tonabersat. As a consequence of slow absorption, daily administration of tonabersat as prophylaxis for migraine attacks is under investigation in ongoing studies.
Dahlöf
C G H
CG
Gothenburg Migraine Clinic, Gothenburg, Sweden. carl.dahlof@migraineclinic.se
Hauge
A W
AW
Olesen
J
J
D000328:Adult; D000700:Analgesics / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D001578:Benzopyrans / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy*; D012449:Safety; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D018170:Sumatriptan / Q000627:therapeutic use; D016896:Treatment Outcome
D000700:Analgesics; D001549:Benzamides; D001578:Benzopyrans; D017366:Serotonin Receptor Agonists; C118706:tonabersat; D018170:Sumatriptan